Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER: Belatacept and Everolimus in Renal Transplantation
NCT04849533Phase 4Unknown
- Sponsor
- University of Cincinnati
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms), sponsored by University of Cincinnati. Primary endpoint: Composite endpoint of patient death, graft loss, or eGFR (MDRD) < 45 mL/min/1.73m2 at 12 months. Status: unknown.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04849533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849533.